|
Market Closed -
London S.E.
11:37:38 2026-09-18 EDT
|
5-day change | 1st Jan Change | ||
| 364.80 CHF | +2.67% |
|
+3.48% | +8.20% |
| 09-13 | Roche Outlines Positive Phase 3 Trial Data for Small-cell Lung Cancer Treatment in China | MT |
| 09-11 | Scholar Rock gets first FDA nod for rare muscle-wasting disease (September 11) | RE |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Data source:
Roche Holding AG(ROP)
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Data source:
Roche Holding AG(ROP)
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
Data source:
Roche Holding AG(ROP)
EBIT
Dividend / Share (DPS)
Data source:
Roche Holding AG(ROP)
Cash or Net Debt
- Stock Market
- Stocks
- ROP Stock
- 0QQ6 Stock
- Consensus Roche Holding AG
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
